Boston Scientific
(NYSE: BSX)
announced that it received FDA 510(k) clearance for its Embold Soft & Packing coils.
Marlborough, Massachusetts-based Boston Scientific designed the coils for use in a variety of embolization procedures. They aid in the minimally invasive treatment for blocking one or more blood vessels, obstructing or reducing blood flow. The procedure stops hemorrhaging, prevents aneurysm ruptures, reduces the size of certain tumors and treats venous abnormalities.
According to the company, the coils strengthen its embolic portfolio. They create a single platform consisting of just three coils, which makes it simpler for physicians to address a variety of patient needs and anatomies. Boston Scientific said this also enables streamlined hospital inventory.
The latest Embold coils build on the success of the company’s Embold Fibered Coil, according to a spokesperson. Boston Scientific launched those last year and they’re currently available in the U.S., Canada and Japan.
“The addition of the Soft & Packing coils now completes the Embold platform, and is expected to build upon the success we’ve already seen with the launch of our Fibered coil last year,” said Peter Pattison, president, interventional oncology & embolization, Boston Scientific. “With the full platform of Embold coils, along with our conformable embolic, Obsidio, we will be able to offer our customers a complementary and highly differentiated portfolio of embolics, enabling them to provide highly personalized care to address the unique needs of their patients.”